Application of Phototherapeutic Keratectomy Mode to Mark the Axis of Astigmatism
Launched by TIANJIN EYE HOSPITAL · Nov 15, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new method to help people with astigmatism, a common vision problem where the eye does not focus light evenly, which can cause blurry vision. The researchers are using a special laser technique called phototherapeutic keratectomy to precisely mark the direction of astigmatism during surgery. This method aims to improve the accuracy of the surgery, making it more effective in correcting astigmatism compared to traditional approaches.
To participate in this trial, you need to be at least 18 years old and should not have any other eye diseases. The trial is currently recruiting participants, and it welcomes individuals of all genders. If you join, you can expect to receive a thorough evaluation and possibly benefit from an innovative treatment designed to improve your vision. It's important to know that the goal of this study is to find a better way to correct astigmatism, which could help many people see more clearly.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • at least 18 years old
- Exclusion Criteria:
- • ocular disease
About Tianjin Eye Hospital
Tianjin Eye Hospital is a leading medical institution specializing in ophthalmology, dedicated to advancing eye health through innovative research and clinical excellence. As a prominent clinical trial sponsor, the hospital is committed to conducting rigorous studies that explore new treatments and therapies for a variety of eye-related conditions. With state-of-the-art facilities and a team of experienced professionals, Tianjin Eye Hospital fosters collaboration with researchers and healthcare providers to enhance patient care and contribute to the global understanding of ocular health. Its focus on patient-centered research ensures that clinical trials are designed to prioritize safety, efficacy, and the well-being of participants.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tianjin, Tianjin, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported